drugset / Trial / NCT04463771
Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.
Phase 2
Completed
206 enrolled
Incyte Corporation
European Network of Gynaecological Oncological Trial Groups (ENGOT) · collabGOG Foundation · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a multicenter, open-label, nonrandomized, Phase 2 umbrella study of retifanlimab in participants who have advanced or metastatic endometrial cancer that has progressed on or after platinum-based chemotherapy. retifanlimab will be administered as monotherapy or in combination with other immunotherapy or targeted agents.
Timeline
- Start
- 2021-01-26
- Primary completion
- 2026-05-29
- Completion
- 2026-05-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Epacadostat | Small molecule | — | Oral |
| Subject | Pemigatinib | Small molecule | — | Oral |
| Subject | Retifanlimab | Monoclonal antibody | — | Intravenous |
| Subject | Tuparstobart | Monoclonal antibody | — | Intravenous |
| Subject | Verzistobart | Monoclonal antibody | — | Intravenous |